Who
Jeffrey W. Albers
Director
Company insider
Files Form 4 as: Director, Spyre Therapeutics; Director, Kymera Therapeutics; CEO and President, Blueprint Medicines; Director, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 359
- Buys
- 0
- Sells
- 74
- Bought
- $0
- Sold
- $69.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 2 Nov 2015
- Last trade
- 7 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $52K5,000 at $10.39 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $522K5,000 at $104.47 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $835K8,000 at $104.38 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M10,000 at $104.68 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $52K5,000 at $10.39 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $522K5,000 at $104.47 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $835K8,000 at $104.38 | filing |
| 7 Aug 2026filed 10 Aug 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M10,000 at $104.68 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 8 Dec 2025filed 8 Dec 2025 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 8 Dec 2025filed 8 Dec 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $71K5,000 at $14.18 | filing |
| 8 Dec 2025filed 8 Dec 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $245K2,748 at $89.32 | filing |
| 8 Dec 2025filed 8 Dec 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $203K2,252 at $90.30 | filing |
| 13 Oct 2025filed 14 Oct 2025 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 13 Oct 2025filed 14 Oct 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $52K5,000 at $10.34 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)KYMR · prnewswire.com · 12 Oct 2026
0 headlines in the last 90 days name Jeffrey W. Albers; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.